Antidepressant use and risk for preeclampsia

Area of Science:

• Perinatal pharmacology
• Reproductive health
• Clinical epidemiology

Background:

• Previous research indicates a potential link between antidepressant use during pregnancy and preeclampsia.
• The comparative safety of different antidepressant classes in pregnancy remains insufficiently understood.
• US nationwide Medicaid Analytic eXtract (MAX) data offer a novel resource for studying medication safety in pregnant populations.

Purpose of the Study:

• To investigate the association between various antidepressant classes and preeclampsia risk in pregnant women.
• To compare the safety profiles of selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants regarding preeclampsia.
• To utilize large-scale administrative healthcare data for robust medication safety analysis in pregnancy.

Main Methods:

• A cohort of 100,942 pregnant women with depression was identified from 2000-2007 MAX data.
• Antidepressant exposure (SSRI, SNRI, tricyclic, bupropion, other) was determined via pharmacy dispensing records during the second and early third trimesters.
• Adjusted relative risks (RRs) and 95% confidence intervals (CIs) were calculated, controlling for potential confounders.

Main Results:

• Preeclampsia risk was 5.4% in non-exposed pregnant women with depression.
• SNRI and tricyclic monotherapy were associated with significantly higher preeclampsia risk compared to no antidepressant use.
• SSRI monotherapy was not associated with an increased risk of preeclampsia; specific SSRIs showed no significant association.
• Compared to SSRIs, SNRI and tricyclic monotherapy demonstrated elevated preeclampsia risks.

Conclusions:

• Serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants are associated with an increased risk of preeclampsia in pregnant women.
• Selective serotonin reuptake inhibitors (SSRIs) appear to have a comparatively safer profile regarding preeclampsia risk.
• These findings highlight the importance of considering specific antidepressant classes when managing depression in pregnancy.